The relationship between type 2 diabetes prescribing levels and HbA1c control across practices participating in the NDA (>50%) has recently been studied.25 Greater HbA1c control was correlated with higher levels of metformin and DPP‐4 inhibitor prescribing, lower prescribing of sulphonylureas, and lower overall spend on diabetes medication per patient (including estimated quantities of blood testing strips and insulin used for people with type 2 diabetes). Here, INS is linked to type 2 diabetes mellitus.